Farnesoid X Receptor Agonist Obeticholic Acid Reduces Kidney Disease in a Mouse Model of Alport Syndrome

被引：0
|
作者：
Jones, Bryce A. [1 ]
Perry, Priscilla E. [1 ]
Davidson, Shania R. [1 ,2 ]
Santiago, Isabel Lopez [1 ,3 ]
Adapa, Sharmila [1 ]
Allen, Katherine C. [1 ]
Dial, Katelyn [1 ]
Rowland, Emma [1 ]
Myakala, Komuraiah [1 ]
Wang, Xiaoxin [1 ]
Levi, Moshe
机构：
[1] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[2] Howard Univ, Coll Arts & Sci, Washington, DC 20059 USA
[3] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
FR-PO688
引用
收藏
页码：511 / 511
页数：1
相关论文
共 50 条
  • [1] Obeticholic Acid, a Farnesoid X Receptor Agonist, Reduces Bile Acid Synthesis in Patients With Primary Bile Acid Diarrhea
    Vassie, Claire
    Nolan, Jonathan D.
    Johnston, Ian M.
    Shapiro, David
    Walters, Julian R.
    GASTROENTEROLOGY, 2014, 146 (05) : S797 - S797
  • [2] OBETICHOLIC ACID, A FARNESOID-X RECEPTOR AGONIST, REDUCES BACTERIAL TRANSLOCATION AND RESTORES INTESTINAL PERMEABILITY IN A RAT MODEL OF CHOLESTATIC LIVER DISEASE
    不详
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S1 - S2
  • [3] The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid
    Walters, J. R. F.
    Johnston, I. M.
    Nolan, J. D.
    Vassie, C.
    Pruzanski, M. E.
    Shapiro, D. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (01) : 54 - 64
  • [4] Process Research and Impurity Control Strategy for Obeticholic Acid, a Farnesoid X Receptor Agonist
    Feng, Wei-Dong
    Zhuo, Song-Ming
    Zhang, Fu-Li
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2019, 23 (09) : 1979 - 1989
  • [5] AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC
    Kowdley, K. V.
    Jones, D.
    Luketic, V.
    Chapman, R.
    Burroughs, A.
    Hirschfield, G.
    Poupon, R.
    Schramm, C.
    Vincent, C.
    Rust, C.
    Pares, A.
    Mason, A.
    Sciacca, C.
    Beecher-Jones, T.
    Bohm, O.
    Castelloe, E.
    Pruzanski, M.
    Shapiro, D.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S13 - S13
  • [6] Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis
    Ho, Peggy P.
    Steinman, Lawrence
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (06) : 1600 - 1605
  • [7] Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis
    Adorini, Luciano
    Rigbolt, Kristoffer
    Feigh, Michael
    Roth, Jonathan
    Erickson, Mary
    PLOS ONE, 2024, 19 (04):
  • [8] Synthesis of obeticholic acid, a farnesoid X receptor agonist, and its major metabolites labeled with deuterium
    Gai, Kuo
    Huang, Yu
    Liu, Baomin
    Zhang, Yinsheng
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2018, 61 (10): : 799 - 804
  • [9] The Effects of Obeticholic Acid, a Farnesoid X Receptor Agonist, in Patients With Chronic Diarrhea Secondary to Crohn's Ileal Disease
    Nolan, Jonathan D.
    Vassie, Claire
    Johnston, Ian M.
    Dew, Tracy
    Shapiro, David
    Walters, Julian R.
    GASTROENTEROLOGY, 2014, 146 (05) : S797 - S797
  • [10] Effect of the farnesoid X receptor agonist, obeticholic acid, in hepatocellular carcinoma: Is it NASH-dependent or -independent?
    Attia, Yasmeen
    Tawfiq, Rasha
    Adel, Aya
    Gibriel, Abdullah
    Hammam, Olfat
    Elmazar, Mohamed
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E520 - E520
12345